Consider first-line consolidation and referral to stem cell transplantation program
| PTCL-NOS |
| ALCL ALK+ with IPI >2 |
| ALCL ALK− with negative DUSP22 rearrangement or TP63 rearrangement |
| Nodal PTCL of TFH origin (including AITL) |
| ATLL, acute or lymphomatous |
| Extranodal T-NK lymphoma, nasal type, stage IV or extranasal |
| Intestinal TCL (EATL, MEITL) |
| Hepatosplenic TCL |
| Primary cutaneous CD8+ aggressive epidermotropic cytotoxic TCL |
| Breast implant–associated ALCL: disease extended beyond the capsule |
| PTCL-NOS |
| ALCL ALK+ with IPI >2 |
| ALCL ALK− with negative DUSP22 rearrangement or TP63 rearrangement |
| Nodal PTCL of TFH origin (including AITL) |
| ATLL, acute or lymphomatous |
| Extranodal T-NK lymphoma, nasal type, stage IV or extranasal |
| Intestinal TCL (EATL, MEITL) |
| Hepatosplenic TCL |
| Primary cutaneous CD8+ aggressive epidermotropic cytotoxic TCL |
| Breast implant–associated ALCL: disease extended beyond the capsule |
EATL, enteropathy-associated TCL; MEITL, monomorphic epitheliotropic intestinal TCL.